NCT03447314View on ClinicalTrials.gov

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

July 1, 2020

Study Completion Date

March 11, 2022

Conditions
Neoplasms
Interventions
DRUG

GSK1795091

GSK1795091 will be available as solution for injection

DRUG

GSK3174998

GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

DRUG

GSK3359609

GSK3359609 will be available as solution for infusion.

DRUG

Pembrolizumab

Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Trial Locations (8)

63110

GSK Investigational Site, St Louis

75230

GSK Investigational Site, Dallas

77030

GSK Investigational Site, Houston

98405

GSK Investigational Site, Tacoma

02215

GSK Investigational Site, Boston

M5G 2M9

GSK Investigational Site, Toronto

1066 CX

GSK Investigational Site, Amsterdam

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT03447314 - Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter